Bio Clinical Collection of Urothelial Carcinoma

NCT04970472 | Recruiting

• 1 other identifier: RC31/21/0070
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to collect tumor samples, urines, stool and blood from patients with urothelial carcinoma. These samples will be stored in a secure and confidential laboratory of the Toulouse University Hospital.

Conditions

Urothelial Carcinoma; Bladder Cancer

Keywords

Urothelial Carcinoma; neoplasm; bladder cancer

Outcome Measures

Primary Outcomes (2)

• Collection and long-term collection of blood, urines, stool and tumor samples from patients with Urothelial bladder carcinoma for future biological and/or surrogate marker studies.

  Transcriptomic analysis

  Day 0

• Collection and long-term collection of blood, urines, stool and tumor samples from patients with Urothelial bladder carcinoma for future biological and/or surrogate marker studies.

  Transcriptomic, proteomic and epigenetic analysis

  during the intervention/procedure/surgery

Study Arms (1)

patients with Urothelial bladder carcinoma

collection of blood, urines, stool and tumor samples

Biological: collection of blood, urines, stool and tumor samples

Interventions

collection of blood, urines, stool and tumor samples BIOLOGICAL

blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.

patients with Urothelial bladder carcinoma

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients will be all enrolled at Toulouse University Hospital during primary cares.

You may qualify if:

• Adult \>18 years old
• Patient with suspected or diagnosed Urothelial carcinoma
• Patients who are willing to consent for this protocol.

You may not qualify if:

• Pregnant or breastfeeding patients
• Patients under 18 years old
• Patients under guardianship or curators
• Patients unable to sign a free and informed consent

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (1)

Rangueil University Hospital

Toulouse, 31059, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Urine, stool, blood and saliva samples will be stored. Tumor samples, collected for primary cares using a punch knife, or a small surgery, will be stored.

MeSH Terms

Conditions

Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasms

Interventions

Defecation

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Digestive System Physiological Phenomena; Digestive System and Oral Physiological Phenomena

Study Officials

• Mathieu Roumiguie, MD, PhD

  University Hospital, Toulouse

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mathieu Roumiguie, MD, PhD

CONTACT

561323229; roumiguie.m@chu-toulouse.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2021
• First Posted: July 21, 2021
• Study Start: November 16, 2021
• Primary Completion (Estimated): July 14, 2026
• Study Completion (Estimated): July 14, 2031
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)